News

The Phase II trial is a double-blind, placebo-controlled trial evaluating 80 high risk geriatric patients following open heart surgery procedures. Patients receive either DCA i.v. or a placebo,

Ongoing pre-clinical studies are being conducted in collaboration with Universite Montpellier in France. These studies on immune-deficient mice are designed to assess and analyze Anavex 7-1037’s ability to

Chimerix has previously demonstrated that single doses of CMX001 provided excellent drug exposure and were well tolerated in healthy volunteers. CMX001 is being developed for smallpox under a

Houston Pharmaceuticals will continue collaborations with both universities and assist in securing grants on behalf of the company. Leonard Ivins, CEO of Edgeline Holdings, said: “Houston Pharmaceuticals will

In the randomized, international, multicenter, open-label Phase III clinical trial that evaluated the safety and efficacy of bendamustine compared to chlorambucil in previously untreated patients with B- chronic

With this payment, Critical Therapeutics has now received a total of $12 million from Dey as part of the companies’ co-promotion agreement. Critical Therapeutics received $3 million from

The new data showed that the median survival of patients treated with Genasense plus chemotherapy who achieved complete remission (CR, defined as complete plus nodular partial response) has

Targacept anticipates that its Phase I program for TC-6499 will include, in addition to the ongoing single dose trial, a multiple rising dose trial. Under its agreement with

XL019 is an investigational small molecule that selectively inhibits the tyrosine kinase JAK2, one of four JAK family members activated in response to cytokines and hematopoietic growth factors.